Abstract: The present invention provides a pharmaceutical composition for treating or preventing a disease caused in the vagina or perivaginal area by a pathogenic virus. The composition contains, as an active ingredient, a compound of an aniline derivative represented by the following formula (I): where W represents S or O, a pharmaceutically acceptable salt thereof, and a hydrate thereof. The pharmaceutical composition is in the form of a vaginal insert (e.g., a vaginal tablet, a vaginal capsule, or a vaginal suppository) containing a granular preparation, which includes core particles and a coating layer covering the core particles. The core particles contain the compound, needle-like and/or approximately column-like-shaped crystalline cellulose, a pharmaceutically acceptable approximately spherical shaped additive, and a nonionic surfactant. The granular preparation is characterized in that, in the core particles, voids are present between the crystalline cellulose and the additive.

Abstract: Disclosed is a pharmaceutical preparation in the form of granules having nuclear particles and a coating layer coating the nuclear particles, wherein the nuclear particles are composed of a drug, a first nuclear-particle component, a second nuclear-particle component and a surfactant; the drug is an aniline derivative represented by the following general formula (I): wherein W represents S or O, or a pharmaceutically acceptable salt thereof, or a hydrate thereof; the first nuclear-particle component is at least one crystalline cellulose having a shape selected from a needle-shape and a substantially columnar shape; and the second nuclear-particle component is at least one pharmaceutically acceptable additive having a substantially spherical shape. The pharmaceutical preparation can contain a therapeutically effective amount of a poorly water-soluble drug (CDK9 inhibitor) and has excellent flowability sufficient for practical production.

Abstract: The present invention provides a compound and a pharmaceutical composition for neuropsychological disorders or malignant tumors, the use of the compound and the pharmaceutical composition, or a method for preventing, improving, inhibiting the development of, and/or treating neuropsychological disorders or malignant tumors with the use of the compound and the pharmaceutical composition.

Abstract: The present invention provides a compound and a pharmaceutical composition for neuropsychological disorders or malignant tumors, the use of the compound and the pharmaceutical composition, or a method for preventing, improving, inhibiting the development of, and/or treating neuropsychological disorders or malignant tumors with the use of the compound and the pharmaceutical composition.

Abstract: The present invention provides a compound and a pharmaceutical composition for neuropsychological disorders or malignant tumors, the use of the compound and the pharmaceutical composition, or a method for preventing, improving, inhibiting the development of, and/or treating neuropsychological disorders or malignant tumors with the use of the compound and the pharmaceutical composition.

Abstract: The present invention provides a compound and a pharmaceutical composition for neuropsychological disorders or malignant tumors, the use of the compound and the pharmaceutical composition, or a method for preventing, improving, inhibiting the development of, and/or treating neuropsychological disorders or malignant tumors with the use of the compound and the pharmaceutical composition.

Abstract: An object of the present invention is to develop a new alternative splicing reporter system and to provide a method for detecting alternative splicing patterns in a multicellular organism more precisely, a method for identifying efficiently substances and gene regions that affect alternative splicing in a multicellular organism, and the like by utilizing the alternative splicing reporter system. Specifically, the present invention relates to a method for detecting alternative splicing in a multicellular organism, and a method for identifying substances and gene regions that affect alternative splicing in a multicellular organism, which use a DNA construct in which at least two different reporter genes are inserted into a specific gene that undergoes alternative splicing, or a combination of DNA constructs (a combination of at least two different DNA constructs) in which DNA construct a reporter gene is inserted into a specific gene that undergoes alternative splicing.

Abstract: Viruses, and particularly RNA viruses, have high mutation rates. Hence, antiviral agents that have been developed to date targeting protease or reverse transcriptase of viruses have quickly lost their effectiveness and resistant viruses have emerged. Also, in recent years, viral diseases caused by various new viruses such as SARS, avian influenza, and the hepatitis C have become social menaces. Therefore, the development of a novel antiviral agent that can cope with a virus resistant to an existing drug or a new virus and has a wide range of applications has been demanded. The present invention provides a novel anti-RNA viral agent and a method for use thereof. The present invention further provides an anti-RNA viral agent that is also effective against a new virus or a drug-resistant virus, and a method for use thereof.

Abstract: The present invention provides a composition of treating, preventing abnormal splicing caused by the excessive kinase induction, which comprises TG003 and a method using the same of treating, preventing abnormal splicing caused by the excessive kinase induction.